Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Saunders Hsu

Pediatric Hematology-Oncology Sacramento, CA Medical Doctor

NPI 1194858936 CMS profile 235432

2825 J St Ste 435, Ste 104, Sacramento, CA 95816

Open in the dashboard

General payments

$3,198

149 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Saunders Hsu of Sacramento, CA is reported in the CMS Open Payments database as having received $3,198 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $79 3
2024 General $468 18
2023 General $480 20
2022 General $595 28
2021 General $718 34
2020 General $342 18
2019 General $516 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saunders Hsu
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Saunders Hsu were reported at $79. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Saunders Hsu Pediatric Hematology-Oncology median Middle half National median
2019 $516 $184 $69–$2,094 $163
2020 $342 $220 $37–$3,941 $114
2021 $718 $366 $63–$4,909 $132
2022 $595 $181 $66–$2,775 $149
2023 $480 $175 $62–$2,600 $160
2024 $468 $227 $66–$2,992 $164
2025 $79 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $536 26 payments
  2. Amgen Inc. $518 22 payments
  3. Alexion Pharmaceuticals, Inc. $437 21 payments
  4. Sobi, Inc $349 17 payments
  5. Servier Pharmaceuticals LLC $224 12 payments
  6. Y-mAbs Therapeutics, Inc. $123 4 payments
  7. Pfizer Inc. $119 5 payments
  8. Bio Products Laboratory USA, Inc. $112 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $89 4 payments
  10. Emmaus Medical, Inc. $63 4 payments
  11. Other $630 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,069 144 payments
  2. Education $129 5 payments
Products named General payments · program years 2019–2025
  1. GAMIFANT $349 17 payments
  2. Nplate $229 10 payments
  3. Blincyto $222 10 payments
  4. PROMACTA $184 10 payments
  5. ULTOMIRIS Rare Disease $155 7 payments
  6. ASPARLAS $137 7 payments
  7. ADAKVEO $136 7 payments
  8. DANYELZA $123 4 payments
  9. Ultomiris Immunology $119 6 payments
  10. OXBRYTA $119 5 payments
  11. Other $1,275 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record